Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Congenital Dyserythropoietic Anemia
NCT07471516Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in congenital dyserythropoietic anemia (CDA), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2026; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
congenital dyserythropoietic anemia (CDA)
Beyond the preview
Go deeper on NCT07471516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471516.